title: [Study of sequence-dependent in vitro effects of zoledronic acid and paclitaxel upon DU145 prostate cancer cells].
abstract: OBJECTIVE
  To investigate the anti-proliferation and pro-apoptotic effects of different sequence schemes of zoledronic acid plus paclitaxel upon the hormone-refractory prostate cancer cell lines DU145 in vitro so as to provide the potentially optimal sequence scheme of these two drugs.
  
  
  METHODS
  MTT assay and Annexin V-FITC/PI double-staining flow cytometry were employed to observe the effects of zoledronic acid plus paclitaxel upon anti-proliferation and apoptosis induction respectively.
  
  
  RESULTS
  Inhibition of cellular growth by (44.17+/-5.81)% was observed under the treatment of paclitaxel and then zoledronic acid. Such a regimen was superior to the treatment of zoledronic acid and then paclitaxel or zoledronic acid (32.81+/-5.13)% plus paclitaxel (36.43+/-5.75)%. In comparisons with other groups, the treatment of paclitaxel and then zoledronic acid induced the maximal apoptosis (14.96%) and necrosis (14.37%) as shown by Annexin V-FITC/PI double-staining flow cytometry.
  
  
  CONCLUSIONS
  For the maximal anti-proliferation and apoptosis, DU145 cells should be treated with paclitaxel then zoledronic acid. Such a regimen provides the optimal scheme for the sequence-dependent treatment.
authors.affiliation: Institute of Urology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Zhong-yi
authors.initials: ZY
authors.lastname: Zhang
authors.forename: Li-qun
authors.initials: LQ
authors.lastname: Zhou
authors.forename: Yi
authors.initials: Y
authors.lastname: Ding
authors.forename: Lin
authors.initials: L
authors.lastname: Yang
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004164:Diphosphonates / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077211:Zoledronic Acid
chemical_list: D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D017239:Paclitaxel